SetSale | $2,000,000 | (Mar 19, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
Certified by Founder
Lodge
Poplar Therapeutics
start up
United States
- Boston, MA
- 09/01/2026
- Series A
- $50,000,000
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.
- Industry Biotechnology Research
- Website https://poplartx.com/
- LinkedIn https://www.linkedin.com/company/poplar-therapeutics/
Beautiful.ai | $45,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)
Homaio | $4,135,744 | (Mar 19, 2026)
Foresight(UK) | $25,000,000 | (Mar 19, 2026)
VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)